Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
MWN-AI** Summary
Pasithea Therapeutics Corp. (Nasdaq: KTTA), a clinical-stage biotechnology company, is set to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The CEO, Tiago Reis Marques, will lead the presentation scheduled for 4:00 PM ET, where attendees will gain insights into the company’s advancements in biopharmaceuticals, particularly focusing on their lead drug candidate, PAS-004. This next-generation macrocyclic MEK inhibitor is geared towards treating NF1-associated plexiform neurofibromas (NF1-PN) and other diseases driven by the MAPK pathway.
Pasithea is currently conducting Phase 1 clinical trials for PAS-004, assessing its efficacy and safety among advanced cancer patients and specifically in adult patients with neurofibromatosis type 1. The company emphasizes its commitment to addressing RASopathies and related health issues, providing promising therapeutic options where existing treatments may fall short.
The conference not only offers a platform for Pasithea to present their research but also facilitates direct engagement with potential investors through one-on-one meetings. Interested parties can access the live webcast of the presentation on Pasithea's website, with replays available for a limited time post-event.
As the company navigates the complexities of clinical trials, the announcement contains forward-looking statements regarding its ongoing research and development activities. These statements highlight the uncertainty and inherent risks faced by Pasithea Therapeutics, including variations in clinical trial outcomes and the potential for regulatory hurdles. Investors and stakeholders are encouraged to consider these factors when evaluating the company's future prospects.
For investor inquiries, Patrick Gaynes from their Investor Relations team can be contacted to provide further insights into Pasithea's ongoing initiatives and strategic direction.
MWN-AI** Analysis
Pasithea Therapeutics (Nasdaq: KTTA) is gearing up to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, where CEO Tiago Reis Marques will discuss their promising drug candidate, PAS-004, a next-generation oral MEK inhibitor. Currently, Pasithea is in critical Phase 1 trials for the treatment of NF1-associated plexiform neurofibromas (NF1-PN) and advanced cancers, raising significant interest among investors and healthcare professionals alike.
With the upcoming presentation, investors should closely monitor key themes such as the efficacy and safety of PAS-004. As the company advances its drug through clinical trials, any interim results or insights provided during the presentation could serve as indicators of its potential success, offering opportunities for traders looking to capitalize on prospective gains. Positive updates or constructive feedback from the investor community during the one-on-one meetings could also influence the company's stock trajectory.
Investors should remain cautious, however, as there are inherent risks in the biotechnology sector. The forward-looking statements included in Pasithea's announcements underscore the uncertainty surrounding clinical trial outcomes, regulatory approvals, and overall market positioning. Unfavorable results from ongoing trials could adversely impact the stock's performance, given the speculative nature of biotech investments.
Given these dynamics, current investors may wish to evaluate their positions according to their risk appetite and investment horizon. For potential investors, it may be prudent to wait for the results of the Phase 1 trials or to analyze the findings shared during the Oppenheimer conference before committing funds. Overall, Pasithea Therapeutics presents an intriguing opportunity with its innovative treatment approach, but caution is warranted until more definitive data is available.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET –
– Webcast may be accessed here –
MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of NF1-associated plexiform neurofibromas (NF1-PN), today announced that Chief Executive Officer Tiago Reis Marques will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25–26, 2026.
The Company’s presentation is scheduled for Thursday, Feb 26 at 4:00-4:30 PM ET in Track 2, and the webcast may be viewed here.
In addition to the presentation, management will be available for one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website. A replay will be available following the live event and will be archived for a limited time.
About Pasithea Therapeutics Corp.
Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).
Forward Looking Statements
This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company’s Phase 1/1b clinical trial of PAS-004 in adult NF1 patients, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.
Pasithea Therapeutics Contact
Patrick Gaynes
Investor Relations
pgaynes@pasithea.com
FAQ**
How does Pasithea Therapeutics Corp. plan to leverage the results from its Phase 1/clinical trials of PAS-004 to increase value for investors holding Pasithea Therapeutics Corp. Warrant KTTAW?
What milestones does Pasithea plan to achieve in 20that could potentially impact the performance of Pasithea Therapeutics Corp. Warrant KTTAW?
Can you explain how the ongoing clinical trials of PAS-004 relate to the broader strategy for Pasithea Therapeutics Corp., particularly for investors considering Pasithea Therapeutics Corp. Warrant KTTAW?
What are the potential implications for investors holding Pasithea Therapeutics Corp. Warrant KTTAW if the clinical trials yield favorable results for PAS-004 in treating NF1-PN?
**MWN-AI FAQ is based on asking OpenAI questions about Pasithea Therapeutics Corp. Warrant (NASDAQ: KTTAW).
NASDAQ: KTTAW
KTTAW Trading
0.0% G/L:
$0.0101 Last:
1,414 Volume:
$0.0101 Open:
